Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non-ischemic Cardiomyopathy
- Sponsor
- Scientific Institute San Raffaele
- Enrollment
- 15000
- Locations
- 1
- Primary Endpoint
- Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the myocardium. The main identified forms include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic cardiomyopathy proper (ACM). More recently, further forms of cardiomyopathy have been described, less common and not uniquely classifiable, including: uncompressed myocardium (LVNC), peripartum cardiomyopathy (PPCM), structural correlates of arrhythmogenic mitral valve prolapse (AMVP), Anderson-Fabry disease (AFD), NICM associated with multi- system neuromuscular or autoimmune diseases, lysosomal diseases, glycogenosis, mitochondrial cytopathies and canal diseases with structural substrates. Finally, there are "overlap" forms, characterized by the sharing in the same subject of characteristic aspects of two or more of the above- mentioned diseases; and of the "undefined" forms, which to date do not reach the diagnostic criteria for any of the above-mentioned diseases.
To the best of current knowledge, there are two points discovered in scientific research, namely the description of the arrhythmogenic and "inflammatory" phenotypes in a broad sense, which are summarized here with the acronym AINICM. In detail:
- Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied.
- Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices.
Based on the clinical presentation, NICM patients will be divided into arrhythmic (AINICM) and non-arrhythmic patients as study and control groups , respectively. The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). Clinical presentations other than arrhythmic, including chest pain and heart failure, will define the control group. In parallel, as shown in Figure 1, patients with any evidence of M-Infl will be compared with those showing no signs of M-Infl.
Detailed Description
This study aims to collect clinical data of both retrospective and prospective patients with suspected or proven NICMs in a registry. The scope of the registry is to answer multiple unsolved questions in the field of AINICM as described below: 1. Improving the diagnostic workup. While genetic test and cardiac magnetic resonance (CMR) constitute the gold standard dagnostic techniques for NICM, it is known that; A) the yield of genetic test is low in NICM; B) the diagnostic performance of CMR may be limited in AINICM, because of cardiac device-related artifacts and/or irregular heartbeat. In this setting, alternative diagnostic techniques, namely computed tomography (CT) scan, positron emission tomography (PET), electroanatomical map (EAM) and endomyocardial biopsy (EMB) may be clinically helpful, as recommended for the investigation of many arrhythmogenic substrates. 2. Identifying disease-specific signatures. Genotype-phenoype associations are expected to benefit from a multimodal and multiparametric approach, in order to allow etiology-specific features in AINICM. Most of the current signatures are limited to combined genotype-CMR studies. Signatures would likely benefit from implementing additional parameters, including arrhythmia features and myocadial inflammatory status. 3. Working our models for risk prediction. Outcomes and arrhythmic risk stratification remain uncertain for most NICM. Based on an advanced multimodal workup, multiparametric risk scores may be created and subsequenlty validated, in order to predict the arrhythmic risk of specific cardiomyopathies. This would improve and refine the scores currently available for a limited number of NICM, such as HCM, classic right ventricular ACM, or cardiomyopathies secondary to LMNA gene mutation. Parameters from clinical arrhythmology and cardiac electrophysiology, as well as those related to inflammation, may improve the current status of the art about risk prediction. 4. Tailoring treatment strategies. A multimodal (i.e. by use of multiple diagnostic techniques) and multidisciplinary (i.e. by means of a team of cardiac electrophysiologists, cardiologists, radiologists, geneticists, immunologists, cardiac pathologists, pediatricians) model may help improving therapeutic strategies in AINICM, as already demonstrated in myocarditis. In detail, treatment options will include guideline-directed cardiological treatment, implantable cardiac devices, antiarrhythmic drugs, immunomodulating agents and catheter ablation of arrhythmias. In this setting, the coordinating center is an internationally recognized third-level referral center for the management of ventricular arrhythmias, and already has advanced facilities, including a dedicated multidisciplinary disease unit for myocarditis and inflammatory cardiomyopathies. In this setting, preliminary evidence suggests a potential benefit from targeting M-Infl even in NICM and AINICM. 5. Allowing direct comparison among specific NICM subgroups. Extensive inclusion criteria, allowing the entry of all NICM in a common registry with homogeneous variables would enable the direct comparison of different AINICM types, by means of multiparametric and multimodal characterization, for the first time including both the electrophysiological and inflammatory viewpoints. This is expected to significantly advance the status of knowledge in the field of NICM.
Investigators
Giovanni Peretto
MD, Principal Investigator
Scientific Institute San Raffaele
Eligibility Criteria
Inclusion Criteria
- •Written informed consent. For pediatric patients, consent will be obtained by parents, according to the laws applicable in each of the participating countries.
- •Clinical suspicion of NICM, and/or proven diagnosis of any NICM and/or genotype consistent with any NICM.
- •NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Exclusion Criteria
- •Absent informed consent.
- •Proven diagnosis of cardiac disease alternative to NICM.
- •Lack of diagnostic workup suitable for diagnosing NICM, detecting arrhythmias, or detecting M-Infl.
- •For patients retrospectively enrolled: lack of active status of follow-up at the enrolling center.
Outcomes
Primary Outcomes
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes
Time Frame: At year 30
Diagnostic concordance in terms of sensitivity, specificity, positive predictive value, negative predictive value
Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup
Time Frame: At year 30
Multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup
Time Frame: At year 30
The multimodal diagnostic workup is a combination of genetic tests, different techniques of cardiac imaging, laboratory tests and biomarkers, histology, and electrophysiological tools, collecting all the clinical variables in a registry
Identification of HCM-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of DCM-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of RCM-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of ACM-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of LVNC-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AMVP-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of PPCM-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of AFD-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of storage and dysmetabolic diseases-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of mitochondrial diseases-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of channelopathies with structural changes-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of overlapping phenotypes-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Identification of undefined phenotypes-specific signatures
Time Frame: At year 30
Identification of disease-specific signatures of diagnosis, etiology, genotype, clinical presentation, arrhythmia type, myocardial inflammation, outcomes, and response to treatment.
Differences in incidence of major events during follow-up in different NICMs
Time Frame: At year 30
Major events: all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearanc e/recurrence of M-Infl. NICMs include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.
Occurrence of major cardiac events in DCM
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in HCM
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in RCM
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in ACM
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in LVNC
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AMVP
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in PPCM
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in AFD
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in storage and dysmetabolic diseases
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in mitochondrial diseases
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in channelopathies with structural changeschannelopathies with structural changes
Time Frame: At 1 year
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in channelopathies with structural changes
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in overlapping phenotypes
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Occurrence of major cardiac events in undefined phenotypes
Time Frame: At 30 years
all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Infl.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM
Time Frame: At 30years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes
Time Frame: At 30 years
Real world efficacy (by comparison of outcomes in patients receiving distinct treatment options) and safety profile (complications, side effects) of every therapeutic strategy, either alone or in combination. Major events are defined as all-cause death, cardiac death, extra-cardiac disease-related death, major ventricular arrhythmias (ventricular tachycardia, fibrillation, appropriate ICD therapy), advanced atrioventricular blocks, heart transplantation, end-stage heart failure, disease-related hospitalizations, left/right ventricular systolic dysfunction, presence/persistence/clearance/recurrence of M-Inf.
Secondary Outcomes
- Assessment of arrhythmia signatures in mitochondrial diseases(At 30 years)
- Assessment of etiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of etiology signatures in overlapping and undefined phenotypes(At 30 years)
- Assessment of pathophysiology signatures in DCM(At 30 years)
- Assessment of pathophysiology signatures in AMVP(At 30 years)
- Assessment of pathophysiology signatures in HCM(At 30 years)
- Assessment of pathophysiology signatures in RCM(At 30 years)
- Assessment of pathophysiology signatures in ACM(At 30 years)
- Assessment of pathophysiology signatures in LVNC(At 30 years)
- Assessment of pathophysiology signatures in PPCM(At 30 years)
- Assessment of pathophysiology signatures in AFD(At 30 years)
- Assessment of pathophysiology signatures in storage and dysmetabolic diseases(At 30 years)
- Assessment of pathophysiology signatures in mitochondrial diseases(At 30 years)
- Assessment of pathophysiology signatures in channelopathies with structural changes(At 5 years)
- Assessment of pathophysiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of pathophysiology signatures in overlapping and undefined phenotypes(At 30 years)
- Assessment of genotype-phenotype signatures in DCM(At 30 years)
- Assessment of genotype-phenotype signatures in HCM(At 30 years)
- Assessment of genotype-phenotype signatures in RCM(At 30 years)
- Assessment of genotype-phenotype signatures in ACM(At 30 years)
- Assessment of genotype-phenotype signatures in LVNC(At 30 years)
- Assessment of genotype-phenotype signatures in AMVP(At 30 years)
- Assessment of genotype-phenotype signatures in PPCM(At 30 years)
- Assessment of genotype-phenotype signatures in AFD(At 30 years)
- Assessment of genotype-phenotype signatures in storage and dysmetabolic diseases(At 30 years)
- Assessment of genotype-phenotype signatures in mitochondrial diseases(At 30 years)
- Assessment of genotype-phenotype signatures in channelopathies with structural changes(At 30 years)
- Assessment of genotype-phenotype signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of genotype-phenotype signatures in overlapping and undefined phenotypes(At 30 years)
- Assessment of arrhythmia signatures in RCM(Every 10 years)
- Assessment of arrhythmia signatures in DCM(At 30 years)
- Assessment of arrhythmia signatures in HCM(At 5 years)
- Assessment of arrhythmia signatures in ACM(Every 30 years)
- Assessment of arrhythmia signatures in LVNC(At 30 years)
- Assessment of arrhythmia signatures in AMVP(At 30 years)
- Assessment of arrhythmia signatures in PPCM(At 30 years)
- Assessment of arrhythmia signatures in AFD(At 30 years)
- Assessment of arrhythmia signatures in storage and dysmetabolic diseases(At 30 years)
- Assessment of arrhythmia signatures in channelopathies with structural changes(At 30 years)
- Assessment of arrhythmia signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of arrhythmia signatures in overlapping and undefined phenotype(At 30 years)
- Assessment of M-Infl signatures in DCM(At 30 years)
- Assessment of M-Infl signatures in HCM(At 30 years)
- Assessment of M-Infl signatures in RCM(At 30 years)
- Assessment of M-Infl signatures in ACM(At 30 years)
- Assessment of M-Infl signatures in LVNC(At 30 years)
- Assessment of M-Infl signatures in AMVP(At 30 years)
- Assessment of M-Infl signatures in PPCM(At 30 years)
- Assessment of M-Infl signatures in AFD(At 30 years)
- Assessment of M-Infl signatures in storage and dysmetabolic diseases(At 30 years)
- Assessment of M-Infl signatures in mitochondrial diseases(At 30 years)
- Assessment of M-Infl signatures in channelopathies with structural changes(At 30 years)
- Assessment of M-Infl signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of M-Infl signatures in overlapping and undefined phenotypes(At 30 years)
- Assessment of extracardiac signatures in DCM(At 30 years)
- Assessment of extracardiac signatures in HCM(At 30 years)
- Assessment of extracardiac signatures in RCM(At 30 years)
- Assessment of extracardiac signatures in ACM(At 30 years)
- Assessment of extracardiac signatures in LVNC(At 30 years)
- Assessment of extracardiac signatures in AMVP(At 30 years)
- Assessment of extracardiac signatures in PPCM(At 30 years)
- Assessment of extracardiac signatures in AFD(At 30 years)
- Assessment of extracardiac signatures in storage and dysmetabolic diseases(At 30 years)
- Assessment of extracardiac signatures in mitochondrial diseases(At 30 years)
- Assessment of extracardiac signatures in channelopathies with structural changes(At 30 years)
- Assessment of extracardiac signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of extracardiac signatures in overlapping and undefined phenotypes(At 30 years)
- Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in DCM(At 30 years)
- Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in HCM(At 30 years)
- Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in RCM(At 30 years)
- Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in ACM(At 30 years)
- Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes(At 30 years)
- Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of multidisciplinary, multimodal, multiparametric diagnostic signatures in overlapping and undefined phenotypes(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in DCM(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in HCM(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in RCM(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in ACM(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in LVNC(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in PPCM(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AMVP(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in AFD(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of laboratory, tissue, cell, metabolic or multiomic signatures in overlapping and undefined phenotypes(At 30 years)
- Assessment of prognostic signatures in DCM(At 30 years)
- Assessment of prognostic signatures in HCM(At 30 years)
- Assessment of prognostic signatures in RCM(At 30 years)
- Assessment of prognostic signatures in ACM(At 30 years)
- Assessment of prognostic signatures in LVNC(At 30 years)
- Assessment of prognostic signatures in AMVP(At 30 years)
- Assessment of prognostic signatures in PPCM(At 30 years)
- Assessment of prognostic signatures in AFD(At 30 years)
- Assessment of prognostic signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of prognostic signatures in overlapping and undefined phenotypes(At 30 years)
- Assessment of response to treatment signatures in DCM(At 30 years)
- Assessment of response to treatment signatures in HCM(At 30 years)
- Assessment of response to treatment signatures in RCM(At 30 years)
- Assessment of response to treatment signatures in ACM(At 30 years)
- Assessment of response to treatment signatures in LVNC(At 30 years)
- Assessment of response to treatment signatures in AMVP(At 30 years)
- Assessment of response to treatment signatures in PPCM(At 30 years)
- Assessment of response to treatment signatures in AFD(At 30 years)
- Assessment of response to treatment signatures in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of response to treatment signatures in overlapping and undefined phenotypes(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in DCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in HCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in RCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in ACM Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in LVNC Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in NICM(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in DCM(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in HCM(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in RCM(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in ACM(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in LVNC(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in AMVP(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in PPCM(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in storage and dysmetabolic diseases(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in mitochondrial diseases(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in channelopathies with structural changes(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in overlapping phenotypes(At 30 years)
- Prevalence of inflammatory activity (presence; type; quantification; pattern) in undefined phenotypes(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in NICMs(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in DCM(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in HCM(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in RCM(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in ACM(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in LVNC(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in AMVP(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in PPCM(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in AFD(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in storage and dysmetabolic diseases(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in mitochondrial diseases(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in channelopathies with structural changes(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in overlapping phenotypes(At 30 years)
- Analysis of correlation between M-Infl and arrhythmia type and ECG features in undefined phenotypes(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in NICMs(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in DCM(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in HCM(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in RCM(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in ACM(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in LVNC(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AMVP(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in PPCM(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in AFD(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in storage and dysmetabolic diseases and mitochondrial diseases(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in channelopathies with structural changes(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in cardiomyopathies associated with systemic, rheumatologic, neuromuscular diseases(At 30 years)
- Analysis of correlation between EMB sampling site and localization of substrate abnormalities at imaging (including substrate-guided EMB or alternative biopsy techniques) in overlapping and/or undefined phenotypes(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in NICMs(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in DCM(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in HCM(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in RCM(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in ACM(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in LVNC(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in AMVP(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in PPCM(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in AFD(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in overlapping and/or undefined phenotypes(At 30 years)
- Diagnostic yield of EMB guided by electroanatomical map in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes, and cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Diagnostic performance of CT scan and/or PET in NICMs, especially when CMR is not feasible(At 30 years)
- Comparison between CMR/CT scan/PET/EAM findings (including fusion imaging) and advanced imaging techniques at echocardiogram in NICMs(At 30 years)
- Analysis of association between M-Infl and arrhythmogenic substrates (cause, types, localization, extension, features, outcomes, response to treatment) in NICMs(At 30 years)
- Evaluation of healing timing of M-Infl in NICMs(At 30 years)
- Association between substrate abnormalities localizations (as assessed by second level imaging techniques) and arrhythmias (type, characteristics and origin site) in NICMs(At 30 years)
- Analysis of association between arrhythmia and inflammation type/features with any other diagnostic exam performed at baseline or during FU(At 30 years)
- Analysis of diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) and safety in different diagnostic techniques (EMB, CMR, CT scan, PET; EAM) in NICMs(At 30 years)
- Assessment of abnormalities in myocardial structure, function, perfusion, and metabolism in NICMs(At 30 years)
- Assessment of non-ischemic myocardial fibrotic scar (presence; type; quantification; pattern; distribution; extension) in NICMs(At 30 years)
- Prevalence of genetic variants (pathogenic, likely-pahogenic, of unknown significance) in NICMs showing distinct arrhythmic phenotypes, M-Infl and scar patterns(At 30 years)
- Genotype-phenotype correlations, as assessed by multimodal and multiparametric diagnostic workup in NICMs (i.e. analysis of association between genotypes and distinct imaging/electrocardiographic/inflammatory/laboratory patterns in patients with NICMs)(At 30 years)
- Evaluation of coronary microvascular disease in NICMs(At 30 years)
- Assessment of myocardial ischemia in NICMs(At 30 years)
- Assessment of autoimmunity in NICMs(At 30 years)
- Identification of any abnormality (genetic, histological, circulating) involving the intercalated disks as known arrhythmogenic players in NICMs(At 30 years)
- Assessment of hemodynamic changes in NICMs(At 30 years)
- Multimodal multiparametric imaging investigation of NICMs(At 30 years)
- Evaluation of differential diagnosis between NICMs and other cardiac diseases(At 30 years)
- Identification of biomarkers of inflammatory stage (acute vs. chronic; active vs. previous) in NICMs(At 30 years)
- Analysis of correlation between local and systemic/peripheral inflammation in NICMs(At 30 years)
- Analysis of the concordance/discordance between the diagnostic findings observed in NICMs by means of distinct techniques, namely EMB and imaging (CMR, CT scan, PET, EAM, echocardiogram)(At 30 years)
- Investigation of infectious, toxicologic, and immunologic factors associated with NICMs(At 30 years)
- Identification of genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic factors with any role in etiology, clinical presentation, diagnosis, prognosis, response to treatment(At 30 years)
- Assessment of the diagnostic yield of different techniques of arrhythmia monitoring in NICMs(At 30 years)
- Invasive and noninvasive investigation of arrhythmogenic substrates in NICMs(At 30 years)
- Diagnostic value of extracardiac diagnostic techniques in NICMs(At 30 years)
- Occurrence of minor events in DCM(At 30 years)
- Occurrence of minor events in HCM(At 30 years)
- Occurrence of minor events in RCM(At 30 years)
- Occurrence in minor events in RCM(At 25 years)
- Occurrence of minor events in ACM(At 30 years)
- Occurrence of minor events in distinct cardiomyopathic phenotypes that have been described in some diseases(At 30 years)
- Occurrence of minor events in distinct cardiomyopathic phenotypes have been described in some diseases(At 5 years)
- Occurrence of minor events in overlapping and undefined phenotypes(At 30 years)
- Description of the natural history of overall and specific forms of NICM, showing distinct arrhythmic phenotypes, M-Infl and scar patterns.(At 30 years)
- Identification of prognostic genetic, circulatory, tissue, cellular, metabolic, molecular, immunologic or multiomic biomarkers for NICMs(At 30 years)
- Identification of biomarkers associated with treatment response for NICMs(At 30 years)
- Identification of cost-effective multimodal and multiparametric risk scores for NICMs(At 30 years)
- Assessment of the prognostic value of arrhythmias in NICMs(At 30 years)
- Assessment of the predictive value of electrophysiological study and electroanatomical arrhythmogenic substrates in risk stratification of NICMs(At 30 years)
- Assessment of the prognostic value of M-Infl in NICMs, i.e. association with major events(At 30 years)
- Assessment of epidemiology signatures in ACM(At 30 years)
- Validation of the reproducibility of existing risk factors and risk stratification scores for NICMs in a real-world population, i.e. verification of their role in predicting major events(At 30 years)
- Assessment of epidemiology signatures in AFD(At 30 years)
- Refinement of risk factors and risk stratification scores for NICMs, i.e. working out of models integrating known and new risk factors for the prediction of major events(At 30 years)
- Elaboration of new risk scores for NICMs, also based on modern technologies of machine learning and artificial intelligence, by identifying the most effective combination of prognostic variables capable of predicting major events(At 30 years)
- Validation of new models in control patient cohorts, i.e. verification of their role in predicting major events(At 30 years)
- Assessment of epidemiology signatures in DCM(At 30 years)
- Assessment of epidemiology signatures in HCM(At 30 years)
- Assessment of epidemiology signatures in RCM(At 30 years)
- Assessment of epidemiology signatures in LVNC(At 30 years)
- Assessment of epidemiology signatures in AMVP(At 30 years)
- Assessment of epidemiology signatures in PPCM(At 30 years)
- Assessment of epidemiology signatures in storage and dysmetabolic diseases(At 30 years)
- Assessment of epidemiology signatures in mitochondrial diseases(At 30 years)
- Assessment of epidemiology signatures in channelopathies with structural changes(At 30 years)
- Assessment of epidemiology signatures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Assessment of epidemiology signatures in overlapping and undefined phenotypes(At 30 years)
- Assessment of etiology signatures in DCM(At 30 years)
- Assessment of etiology signatures in HCM(At 30 years)
- Assessment of etiology signatures in RCM(At 30 years)
- Assessment of etiology signatures in ACM(At 30 years)
- Assessment of etiology signatures in LVNC(At 30 years)
- Assessment of etiology signatures in AMVP(At 30 years)
- Assessment of etiology signatures in PPCM(At 30 years)
- Assessment of etiology signatures in AFD(At 30 years)
- Assessment of etiology signatures in storage and dysmetabolic diseases(At 30 years)
- Assessment of etiology signatures in mitochondrial diseases(At 30 years)
- Assessment of etiology signatures in channelopathies with structural changes(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AMVP Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in PPCM Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in AFD Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in storage and dysmetabolic diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in mitochondrial diseases Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in channelopathies with structural changes Efficacy of pharmacological antiarrhythmic treatment on major and minor events(At 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(At 30 years)
- Evaluation of efficacy of pharmacological antiarrhythmic treatment on major and minor events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(By 30 years)
- Evaluation of efficacy of treatment, defined based on the incidence of minor events during follow-up in overlapping and undefined phenotypes Efficacy of pharmacological antiarrhythmic treatment on major and minor events(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in DCM(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in HCM(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in RCM(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in ACM(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in LVNC(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in AMVP(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in PPCM(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in AFD(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in storage and dysmetabolic diseases, mitochondrial diseases, channelopathies with structural changes(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases(By 30 years)
- Efficacy of etiology-specific treatment on arrhythmic and inflammatory outcomes, as well as on major and minor events in overlapping and undefined phenotypes(By 30 years)
- Identification of criteria for device implants (PM, ICD, S-ICD, CRT-D...) in NICMs patients(By 30 years)
- Identification of the most suitable therapeutic strategies based on indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes(By 30 years)
- Identification of the best candidates to multidisciplinary management of NICMs(By 30 years)
- Indication and timing for device (ICD, CRT-D) implant in primary prevention, based on multidisciplinary, multimodal, multiparametric risk assessment in NICMs, and in relation to different general and etiology-dependent treatments(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in DCM patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in HCM patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in RCM patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in ACM patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in LVNC patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in PPCM patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in AMVP patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in AFD patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in storage and dysmetabolic diseases patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in mitochondrial diseases patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in channelopathies with structural changes patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of multidisciplinary patient - tailored approach for the management of inflammation and comorbidities in cardiomyopathies associated with overlapping and undefined phenotypes patients, i.e. effects on major and minor events(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in DCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in HCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in RCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in ACM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in LVNC patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in AMVP patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in PPCM patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in AFD patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in storage and dysmetabolic diseases patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in mitochondrial diseases patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in channelopathies with structural change patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases patients, , i.e. effects on major and minor events(By 30 years)
- Efficacy of support treatment, optimal cardiological treatment, and treatment options for heart failure in overlapping and undefined phenotypes patients, , i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in storage and dysmetabolic diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in channelopathies with structural changes i.e. effects on major and minor events.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.(By 30 years)
- Efficacy of immunomodulatory, immunosuppressive and anti-inflammatory therapy, including biological targeted therapy in overlapping and undefined phenotypes i.e. effects on major and minor events.(By 30 years)
- Efficacy of etiology -specific treatments, including those aimed to target extra - cardiac disease manifestations in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in storage and dysmetabolic diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.(By 30 years)
- Efficacy of etiology-specific treatments, including those aimed to target extra-cardiac disease manifestations in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in storage and dysmetabolic diseases, mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of replacement therapy, molecular therapy, gene therapy in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in DCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in HCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in RCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in ACM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in LVNC i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in AMVP i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in PPCM i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in AFD i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in storage and dysmetabolic diseases, mitochondrial diseases i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in channelopathies with structural changes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases i.e. effects on major and minor events.(By 30 years)
- Efficacy of heart transplantation and other treatment for end-stage heart failure in overlapping and undefined phenotypes i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in DCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in HCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in RCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in ACM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in LVNC, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in AMVP, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in PPCM, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in AFD, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in storage and dysmetabolic diseases, mitochondrial diseases, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in channelopathies with structural changes, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, i.e. effects on major and minor event i.e. effects on major and minor events.(By 30 years)
- Efficacy of surgical or hemodynamic procedures in overlapping and undefined phenotypes, i.e. effects on major and minor event i.e. effects on major and minor events. Analysis of safety, i.e. incidence of adverse reactions.(By 30 years)
- Investigation of cardiac device implant in primary and secondary prevention, in all patients, as well as in subgroups with and without M-Infl in NICMs(By 30 years)
- Investigation of ablation of cardiac arrhythmias (indications, patient selection, timing, risk-to-benefit ratio, side effects, duration, challenges, relationships with outcomes) in NICMs(By 30 years)
- Role of ablation (any technique) on arrhythmic outcomes in NICMs, in all patients, as well as in subgroups with and without arrhythmias and MInfl(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in HCM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in ACM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in LVNC, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in AMVP, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in PPCM, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in AFD, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in storage and dysmetabolic diseases, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in mitochondrial diseases, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in channelopathies with structural changes, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures rheumatologic or neuromuscular diseases(By 30 years)
- Indications and optimal timing for any electrophysiological or interventional procedures in overlapping and undefined phenotypes, i.e. comparison of incidence of major and minor events in patients undergoing treatment at different timings(By 30 years)